Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTVwOE[2OkDPxE1? MonYV2FPT0WU
DOHH-2 M3j3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzVTWM2OD17LkO1Olg6KM7:TR?= NWjpV|l7W0GQR1XS
no-10 Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;FdmlEPTB;OT65NFM6KM7:TR?= MYrTRW5ITVJ?
LS-513 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFzLkO1OFch|ryP M{X6WnNCVkeHUh?=
ALL-PO NEHyOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf0TWM2OD1zMT63O|M1KM7:TR?= NHfYfIdUSU6JRWK=
8-MG-BA M4LLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF|LkGxNlMh|ryP MYDTRW5ITVJ?
RPMI-8402 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnftTWM2OD1zNT64OVM4KM7:TR?= MnL4V2FPT0WU
EoL-1-cell MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImzZ4VKSzVyPUG4MlU6PDhizszN NF3UbYpUSU6JRWK=
NALM-6 M1zzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r4O2lEPTB;MUmuNFE3PyEQvF2= M1r5fXNCVkeHUh?=
DEL MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3qTo9KSzVyPUKwMlE1PzFizszN MVnTRW5ITVJ?
SR MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fYOmlEPTB;MkOuOlcyPSEQvF2= MmHOV2FPT0WU
697 NIXXXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S3UmlEPTB;Mk[uOlE2PSEQvF2= MXvTRW5ITVJ?
COLO-829 NUnkeJRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjsbppWUUN3ME2yOk45PDh|IN88US=> MlfqV2FPT0WU
EVSA-T NGLrSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK1TWM2OD1{Nz61OVYyKM7:TR?= MXvTRW5ITVJ?
ATN-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTnSoNKSzVyPUOxMlI{OjlizszN MYLTRW5ITVJ?
L-363 M3H4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTNzLke0OlEh|ryP MWPTRW5ITVJ?
LAMA-84 Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTN{LkWyNVEh|ryP MUPTRW5ITVJ?
NOS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHRc25KSzVyPUO0MlI6PTZizszN NHHre3BUSU6JRWK=
BB30-HNC NXLjRXpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G2V2lEPTB;M{SuN|MxPiEQvF2= M33qRnNCVkeHUh?=
BC-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLNTWM2OD1|Nz65O|Q3KM7:TR?= NWHWfHh{W0GQR1XS
IST-SL2 M2TsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH4eZNKSzVyPUO4MlIzPCEQvF2= NFHpfGtUSU6JRWK=
D-392MG NV:5NYg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\mS2lEPTB;NECuNlIyPSEQvF2= MWrTRW5ITVJ?
no-11 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTRyLkW1NlEh|ryP MW\TRW5ITVJ?
LC4-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm5bJh2UUN3ME20NE45PzF4IN88US=> NXPndIJFW0GQR1XS
A388 MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v3[GlEPTB;NEKuOVg1QCEQvF2= MXjTRW5ITVJ?
NTERA-S-cl-D1 NH:wbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;hTWM2OD12Mj63NFc1KM7:TR?= MWDTRW5ITVJ?
CESS NViw[Y5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\qelR2UUN3ME20OE4zOjN{IN88US=> MnH6V2FPT0WU
RS4-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7XNFBKSzVyPUS5MlA6OzhizszN M1flbnNCVkeHUh?=
MS-1 Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHTe3BKSzVyPUWwMlk{PTFizszN NUL1VVF[W0GQR1XS
CTV-1 M{\Xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTa[XBHUUN3ME21NU4xPzRizszN NGfhd4pUSU6JRWK=
D-502MG NX74cppVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULSZ4E3UUN3ME21NU43OjdzIN88US=> M12wW3NCVkeHUh?=
ML-2 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfWV|RKSzVyPUWyMlkyQTVizszN NWH2XWdEW0GQR1XS
SK-NEP-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz0TWM2OD13Mz6zPVI{KM7:TR?= NWTVOYpUW0GQR1XS
LOXIMVI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rPZmlEPTB;NUOuOVg5PCEQvF2= NVT6bWhpW0GQR1XS
DJM-1 MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTV4LkOzPVEh|ryP Mn:2V2FPT0WU
GI-1 NGnUdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTV4Lk[xOFkh|ryP Mn3oV2FPT0WU
IST-MES1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfGbGszUUN3ME22NE42PDl|IN88US=> NGPOVJBUSU6JRWK=
MV-4-11 NWLLUlllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm1Slc5UUN3ME22NE43PTN6IN88US=> MUnTRW5ITVJ?
OVCAR-4 NV7VOYxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTZ|LkW2OVch|ryP M1XwNnNCVkeHUh?=
KE-37 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3mzbWlEPTB;Nk[uNlY3QCEQvF2= NXO3XW06W0GQR1XS
D-542MG M4nheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TvT2lEPTB;NkiuOFE{PSEQvF2= NHHxdFhUSU6JRWK=
MHH-PREB-1 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPxNJlKSzVyPUeyMlg1PDFizszN MkHBV2FPT0WU
MRK-nu-1 NV64S281T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTd|LkS3NFUh|ryP M2fhUHNCVkeHUh?=
D-247MG M2fSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;ER3NKSzVyPUezMlU1PDJizszN NUjNR5ZIW0GQR1XS
OCI-AML2 NFW0eVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGiyOWVKSzVyPUe2Mlk{PjlizszN MXrTRW5ITVJ?
LP-1 MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrFR3BwUUN3ME24Nk45PzNzIN88US=> Mlr6V2FPT0WU
HCC1599 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HNSGlEPTB;OESuNlg{PyEQvF2= M2P1XnNCVkeHUh?=
KARPAS-45 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTh2Lk[5PVIh|ryP NFf4TndUSU6JRWK=
BE-13 M1TrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DQWmlEPTB;OUmuNFQ4PyEQvF2= MnrQV2FPT0WU
GCIY M2D1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHtTWM2OD17OT6wPVU1KM7:TR?= NFzib4JUSU6JRWK=
BV-173 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFyMD6zNlUh|ryP M2fnNnNCVkeHUh?=
LB2518-MEL NIXkdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG3Z3R5UUN3ME2xNFAvPzh7IN88US=> MVHTRW5ITVJ?
KS-1 M{m3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTCU3R1UUN3ME2xNFEvPjN7IN88US=> MWHTRW5ITVJ?
MOLT-16 M4\I[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;OTWM2OD1zMESuPVg3KM7:TR?= NVflRZhnW0GQR1XS
NCI-H1770 NVfveYExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPiTWM2OD1zMEiuO|g1KM7:TR?= Mn\VV2FPT0WU
NCI-H82 NGPwOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrHTWM2OD1zMUCuPVc3KM7:TR?= MYrTRW5ITVJ?
NCCIT NHPK[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLYc25CUUN3ME2xNVIvPTJ7IN88US=> NX\QWVdqW0GQR1XS
KALS-1 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuyeI11UUN3ME2xNVUvQTRzIN88US=> MVrTRW5ITVJ?
LB2241-RCC NHLRe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnOUZpKSzVyPUGxOk43PzlizszN MlfXV2FPT0WU
HH NHzjboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrrTWM2OD1zMUeuN|k2KM7:TR?= NEC4WXhUSU6JRWK=
HD-MY-Z MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGyXYZKSzVyPUGxPE41QDhizszN MlzRV2FPT0WU
EB-3 NFm0b|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DFUWlEPTB;MUKzMlA6PCEQvF2= NGr1eIlUSU6JRWK=
BL-70 NH3l[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPz[o5KSzVyPUGyN{4yOjdizszN NUHXWlQ4W0GQR1XS
K-562 NYjZVWFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2GxN2lEPTB;MUK2MlI1PSEQvF2= MWrTRW5ITVJ?
HT-144 NHTUcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHNXmVQUUN3ME2xN|MvOTZ2IN88US=> M3zjc3NCVkeHUh?=
PF-382 NITqS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPKZ2F7UUN3ME2xN|QvOzZzIN88US=> M33lcnNCVkeHUh?=
RPMI-8226 NUf1S45LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M135SWlEPTB;MUO1MlA1PSEQvF2= MkTTV2FPT0WU
NCI-H1355 M2nvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXuTWM2OD1zM{WuOVg4KM7:TR?= MXTTRW5ITVJ?
LXF-289 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PVOGlEPTB;MUO5Mlc5OSEQvF2= NW\idnRWW0GQR1XS
NCI-H69 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF2Mj65N|Ih|ryP M3z4NnNCVkeHUh?=
SK-MEL-1 NIPyZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe5WFNKSzVyPUG0O{4yOyEQvF2= Mn;JV2FPT0WU
KARPAS-299 NF7MeXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q3bmlEPTB;MUS5MlEzKM7:TR?= Mn71V2FPT0WU
GB-1 M1HXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\6TWM2OD1zNEmuN|IzKM7:TR?= M4jSRnNCVkeHUh?=
CMK MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF2OT61NVUh|ryP MXfTRW5ITVJ?
MPP-89 M1SwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rmRWlEPTB;MUW2MlA{PSEQvF2= NUfx[4V7W0GQR1XS
KU812 NVPLe5BrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHNToRKSzVyPUG2NU46ODJizszN MnftV2FPT0WU
REH NFrac3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37IWmlEPTB;MU[yMlEzPSEQvF2= M2PxUXNCVkeHUh?=
NEC8 M{PLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF4NT6wNlYh|ryP Mo\wV2FPT0WU
KP-N-YS NUTxTplxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HYdWlEPTB;MU[4MlM6PSEQvF2= NULJN3hlW0GQR1XS
Ramos-2G6-4C10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnZPYg1UUN3ME2xOlkvQTF3IN88US=> NEm3dmRUSU6JRWK=
Becker NEnNUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{OyXmlEPTB;MUe0MlE5KM7:TR?= Mn3EV2FPT0WU
LB647-SCLC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3LeFE{UUN3ME2xO|UvQDR3IN88US=> NXnqN3VXW0GQR1XS
LU-139 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;0TWM2OD1zN{iuNFE6KM7:TR?= MnHMV2FPT0WU
QIMR-WIL M2DKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle4TWM2OD1zN{muOlQ3KM7:TR?= MnflV2FPT0WU
NCI-H1395 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v0S2lEPTB;MUe5Mlk6PiEQvF2= MkLXV2FPT0WU
NOMO-1 M1\SWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7TTWM2OD1zOEKuPFUh|ryP M4njZ3NCVkeHUh?=
GI-ME-N MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrjXG83UUN3ME2xPFcvQTZ7IN88US=> NYHoZW9WW0GQR1XS
KMS-12-PE NXXmZll{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PlPWlEPTB;MUi5MlI4OyEQvF2= MofBV2FPT0WU
Daudi M1r0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF7MT6xNlgh|ryP NHW3T29USU6JRWK=
LB996-RCC NES3fWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rQ[mlEPTB;MUmxMlY6QSEQvF2= M3;DdnNCVkeHUh?=
NCI-H2107 NUXrdoJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{eySGlEPTB;MUmzMlc{QSEQvF2= M2mxWnNCVkeHUh?=
SK-PN-DW M1\Gcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF7ND63NVkh|ryP NHjPc2JUSU6JRWK=
MC-CAR MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfzNWdKSzVyPUKwNk4zPTNizszN M1zpVXNCVkeHUh?=
SNB75 NHn3NJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHiyVHhKSzVyPUKyNU46PCEQvF2= NGX2WGpUSU6JRWK=
ES4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJ{Mz63PFMh|ryP NEHENYxUSU6JRWK=
KARPAS-422 M320[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTRTWM2OD1{MkiuN|UzKM7:TR?= NX3yNm9JW0GQR1XS
NCI-H1648 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHiV3FKSzVyPUKyPU41QDlizszN M1yzUXNCVkeHUh?=
ES6 M1zvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjWTWM2OD1{M{muOFMh|ryP MVzTRW5ITVJ?
KNS-81-FD NXf1VJNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHMTWM2OD1{NEGuNVk4KM7:TR?= NF\iNWNUSU6JRWK=
JAR NEfLcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvnTWM2OD1{NU[uNlI2KM7:TR?= M2jaZXNCVkeHUh?=
NB1 NGD3UGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ4MD61NVYh|ryP MVXTRW5ITVJ?
D-336MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3kTWM2OD1{NkCuOlk5KM7:TR?= MlPJV2FPT0WU
BC-3 M4G4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WzWGlEPTB;Mk[1MlE4QCEQvF2= NEjkN2ZUSU6JRWK=
HCC2218 NHPZOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LLXmlEPTB;Mk[2MlQyPSEQvF2= MmPOV2FPT0WU
TE-9 M3X5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT1N4ZNUUN3ME2yOlYvPjJ5IN88US=> NGnmNmRUSU6JRWK=
LB1047-RCC NVfTb2FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLITWM2OD1{Nk[uO|U{KM7:TR?= NFftUJhUSU6JRWK=
CTB-1 NHLPfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJ4OT65O|Mh|ryP NUf6eItiW0GQR1XS
NB7 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfUfZdKSzVyPUK3NUDPxE1? MV\TRW5ITVJ?
ST486 NFP3ZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K1TmlEPTB;Mke3MlQyOiEQvF2= Ml;lV2FPT0WU
HCC1187 Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDsOmpbUUN3ME2yPFIvQDFzIN88US=> NYXEbGR{W0GQR1XS
NCI-SNU-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1foVmlEPTB;Mki0MlI1QCEQvF2= MmHrV2FPT0WU
COR-L279 M2ftPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmxTWM2OD1{OUGuOVg1KM7:TR?= NI[xUYZUSU6JRWK=
ES8 NHLx[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLJNm9KSzVyPUK5OE4yQDJizszN NGTzfFZUSU6JRWK=
U-698-M M13RVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7iTWM2OD1{OUiuNlQ{KM7:TR?= NFXtZW5USU6JRWK=
HEL NW\UZZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEniNIJKSzVyPUOwPU4yPDlizszN NGnvPWJUSU6JRWK=
KINGS-1 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fhS2lEPTB;M{GwMlY4PCEQvF2= NFnwV|hUSU6JRWK=
KY821 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHGTWM2OD1|M{[uOVk2KM7:TR?= M4K0fnNCVkeHUh?=
MZ1-PC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTCNFVrUUN3ME2zOFUvPjF6IN88US=> MkD5V2FPT0WU
LS-411N M2PVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[zTWM2OD1|NUSuOlYh|ryP M3;hXXNCVkeHUh?=
SIG-M5 NFzpUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vHbWlEPTB;M{W5Mlc5OiEQvF2= M4PEeXNCVkeHUh?=
HT NYL6cGtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTN4Nz63NVEh|ryP MUHTRW5ITVJ?
HC-1 NEXxb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnBTVN2UUN3ME2zOlcvPzh5IN88US=> NYr0dFBDW0GQR1XS
NCI-H1694 NFXyW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n1UWlEPTB;M{eyMlk{PCEQvF2= MXzTRW5ITVJ?
BB65-RCC NH[yVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HUOGlEPTB;M{e2MlI1PSEQvF2= M2G0c3NCVkeHUh?=
HAL-01 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq2SYdKSzVyPUO3PU45OzhizszN MlH2V2FPT0WU
ARH-77 MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3iVHhGUUN3ME2zPVQvODB6IN88US=> M1XmbnNCVkeHUh?=
MZ7-mel MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jFb2lEPTB;M{m3MlI{OyEQvF2= NH;mTpdUSU6JRWK=
SIMA MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q3UWlEPTB;NECzMlk{OyEQvF2= MlriV2FPT0WU
DG-75 NX;yfZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvjUldCUUN3ME20NVUvPjl6IN88US=> NF\aT5BUSU6JRWK=
HUTU-80 M2HQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV72SYVZUUN3ME20NVkvOTh3IN88US=> M1zmc3NCVkeHUh?=
KNS-42 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLtTWM2OD12MkWuPFE2KM7:TR?= MlzLV2FPT0WU
SH-4 M4XMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR{Nz61OlUh|ryP M4G5V3NCVkeHUh?=
L-540 M2e2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTR|MT6wN|Eh|ryP MU\TRW5ITVJ?
NB10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTVRmo4UUN3ME20OFEvOjN2IN88US=> M17HTHNCVkeHUh?=
ES1 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO0ZodKSzVyPUS1Nk44PTNizszN MlLYV2FPT0WU
KMOE-2 M4fWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXRXZZKSzVyPUS1Ok44OTFizszN MmXmV2FPT0WU
MC116 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHRTWM2OD12NUiuNVE3KM7:TR?= MXrTRW5ITVJ?
RCC10RGB NHjJ[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTR4MD6wNFUh|ryP M3zJN3NCVkeHUh?=
RL95-2 NFnWb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVyxTFBlUUN3ME20OlAvOjN5IN88US=> Ml\ZV2FPT0WU
Raji NYTOZnhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HaVGlEPTB;NE[4MlE1OyEQvF2= MWPTRW5ITVJ?
CAS-1 NF\5Vm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWwTWM2OD12N{KuNFc{KM7:TR?= NIDhN|FUSU6JRWK=
Calu-6 NGnpblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzrTWM2OD12N{WuNlY2KM7:TR?= M{X5XnNCVkeHUh?=
KG-1 NY\FOG9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTR5OD60OEDPxE1? MlrOV2FPT0WU
LB771-HNC NWLMRXpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHYTWM2OD12OEKuNlMzKM7:TR?= NXzRUXZMW0GQR1XS
ACN NIrCe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR7Mz61PVkh|ryP M1q2SXNCVkeHUh?=
KM12 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HYVmlEPTB;NEm2MlU5QSEQvF2= MoTUV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID